Literature DB >> 10918065

Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1.

N Wang1, D L Silver, P Costet, A R Tall.   

Abstract

Mutations of the ABC1 transporter have been identified as the defect in Tangier disease, characterized by low HDL and cholesterol ester accumulation in macrophages. A full-length mouse ABC1 cDNA was used to investigate the mechanisms of lipid efflux to apoA-I or HDL in transfected 293 cells. ABC1 expression markedly increased cellular cholesterol and phospholipid efflux to apoA-I but had only minor effects on lipid efflux to HDL. The increased lipid efflux appears to involve a direct interaction between apoA-I and ABC1, because ABC1 expression substantially increased apoA-I binding at the cell surface, and chemical cross-linking and immunoprecipitation analysis showed that apoA-I binds directly to ABC1. In contrast to scavenger receptor BI (SR-BI), another cell surface molecule capable of facilitating cholesterol efflux, ABC1 preferentially bound lipid-free apoA-I but not HDL. Immunofluorescence confocal microscopy showed that ABC1 is primarily localized on the cell surface. In the absence of apoA-I, cells overexpressing ABC1 displayed a distinctive morphology, characterized by plasma membrane protrusions and resembling echinocytes that form when there are excess lipids in the outer membrane hemileaflet. The studies provide evidence for a direct interaction between ABC1 and apoA-I, but not HDL, indicating that free apoA-I is the metabolic substrate for ABC1. Plasma membrane ABC1 may act as a phospholipid/cholesterol flippase, providing lipid to bound apoA-I, or to the outer membrane hemileaflet.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10918065     DOI: 10.1074/jbc.M005438200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  151 in total

Review 1.  Tangier disease as a test of the reverse cholesterol transport hypothesis.

Authors:  A R Tall; N Wang
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  Is it time to modify the reverse cholesterol transport model?

Authors:  A R Tall; N Wang; P Mucksavage
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 3.  Regulation and mechanisms of macrophage cholesterol efflux.

Authors:  Alan R Tall; Philippe Costet; Nan Wang
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 4.  Intracellular cholesterol transport.

Authors:  Frederick R Maxfield; Daniel Wüstner
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

5.  Characterization of apoA-I-dependent lipid efflux from adipocytes and role of ABCA1.

Authors:  Alisha D Howard; Philip B Verghese; Estela L Arrese; Jose L Soulages
Journal:  Mol Cell Biochem       Date:  2010-06-10       Impact factor: 3.396

6.  Impact of self-association on function of apolipoprotein A-I.

Authors:  Shobini Jayaraman; Sumiko Abe-Dohmae; Shinji Yokoyama; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

7.  ATP-binding cassette transporter ABCA4: molecular properties and role in vision and macular degeneration.

Authors:  Robert S Molday
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

Review 8.  ATP binding cassette transporter A1--key roles in cellular lipid transport and atherosclerosis.

Authors:  Neelam Srivastava
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

9.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.

Authors:  Laurent Yvan-Charvet; Mollie Ranalletta; Nan Wang; Seongah Han; Naoki Terasaka; Rong Li; Carrie Welch; Alan R Tall
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Differential phospholipid substrates and directional transport by ATP-binding cassette proteins ABCA1, ABCA7, and ABCA4 and disease-causing mutants.

Authors:  Faraz Quazi; Robert S Molday
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.